Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study.

Vasiliki MamakouSophie HackingerEleni ZenginiEvgenia TsompanakiEirini MarouliIoannis SerafetinidisBram PrinsAthina KarabelaEirini GlezouLorraine SouthamNigel W RaynerKaroline KuchenbaeckerKlea LamnissouVassilis KontaxakisGeorge DedoussisFragiskos GonidakisAnastasia ThanopoulouNikolaos TentolourisEleftheria Zeggini

Published in: BMC psychiatry (2018)

We find an increased risk of T2D in patients with SCZ who take a combination of at least three different psychotropic medication classes compared to patients whose medication consists only of one or two classes of drugs.

Keyphrases

combination therapy
type diabetes
end stage renal disease
ejection fraction
healthcare
chronic kidney disease
newly diagnosed
prognostic factors
cardiovascular disease
emergency department
glycemic control
patient reported outcomes
adipose tissue
climate change
skeletal muscle